Abstract
Neuroendocrine tumors represent a spectrum of tumor types with different biologic and clinical features. The morphologic types include the low-grade typical and atypical carcinoids and the high-grade small cell and large cell neuroendocrine carcinomas (NECs). Cytogenetic descriptions of high-grade NECs are rare. Complete karyotypic descriptions of 34 high-grade NECs are reviewed: 7 extrapulmonary small cell NECs, 3 metastatic NECs of unknown primary, and 24 small cell lung carcinomas (SCLCs). Chromosomal deletions are more frequent than gains and often involve the entire chromosome arm. Typical aberrations are deletions of chromosome 3p, 5q, 10q, and 17p and gains of 1q, 3q, and 5p occurring as isochromosomes. Non-small cell lung cancers (NSCLCs) have different cytogenetic aberrations, but those with a metastatic phenotype display the identical aberrations as SCLC, a tumor known for its metastatic phenotype at onset. A genetic classification of lung cancer that incorporates the pattern of recurrent chromosome aberrations may be a better predictor of clinical outcome than a morphologic classification.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 33-41 |
| Number of pages | 9 |
| Journal | Cancer Genetics and Cytogenetics |
| Volume | 155 |
| Issue number | 1 |
| DOIs | |
| State | Published - Nov 2004 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Genetics
- Molecular Biology
Cite this
High-grade neuroendocrine carcinomas display unique cytogenetic aberrations. / Welborn, Jeanna L; Jenks, Helen; Taplett, Janet; Walling, Paula.
In: Cancer Genetics and Cytogenetics, Vol. 155, No. 1, 11.2004, p. 33-41.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - High-grade neuroendocrine carcinomas display unique cytogenetic aberrations
AU - Welborn, Jeanna L
AU - Jenks, Helen
AU - Taplett, Janet
AU - Walling, Paula
PY - 2004/11
Y1 - 2004/11
N2 - Neuroendocrine tumors represent a spectrum of tumor types with different biologic and clinical features. The morphologic types include the low-grade typical and atypical carcinoids and the high-grade small cell and large cell neuroendocrine carcinomas (NECs). Cytogenetic descriptions of high-grade NECs are rare. Complete karyotypic descriptions of 34 high-grade NECs are reviewed: 7 extrapulmonary small cell NECs, 3 metastatic NECs of unknown primary, and 24 small cell lung carcinomas (SCLCs). Chromosomal deletions are more frequent than gains and often involve the entire chromosome arm. Typical aberrations are deletions of chromosome 3p, 5q, 10q, and 17p and gains of 1q, 3q, and 5p occurring as isochromosomes. Non-small cell lung cancers (NSCLCs) have different cytogenetic aberrations, but those with a metastatic phenotype display the identical aberrations as SCLC, a tumor known for its metastatic phenotype at onset. A genetic classification of lung cancer that incorporates the pattern of recurrent chromosome aberrations may be a better predictor of clinical outcome than a morphologic classification.
AB - Neuroendocrine tumors represent a spectrum of tumor types with different biologic and clinical features. The morphologic types include the low-grade typical and atypical carcinoids and the high-grade small cell and large cell neuroendocrine carcinomas (NECs). Cytogenetic descriptions of high-grade NECs are rare. Complete karyotypic descriptions of 34 high-grade NECs are reviewed: 7 extrapulmonary small cell NECs, 3 metastatic NECs of unknown primary, and 24 small cell lung carcinomas (SCLCs). Chromosomal deletions are more frequent than gains and often involve the entire chromosome arm. Typical aberrations are deletions of chromosome 3p, 5q, 10q, and 17p and gains of 1q, 3q, and 5p occurring as isochromosomes. Non-small cell lung cancers (NSCLCs) have different cytogenetic aberrations, but those with a metastatic phenotype display the identical aberrations as SCLC, a tumor known for its metastatic phenotype at onset. A genetic classification of lung cancer that incorporates the pattern of recurrent chromosome aberrations may be a better predictor of clinical outcome than a morphologic classification.
UR - http://www.scopus.com/inward/record.url?scp=7444252730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7444252730&partnerID=8YFLogxK
U2 - 10.1016/j.cancergencyto.2004.03.001
DO - 10.1016/j.cancergencyto.2004.03.001
M3 - Article
VL - 155
SP - 33
EP - 41
JO - Cancer Genetics and Cytogenetics
JF - Cancer Genetics and Cytogenetics
SN - 0165-4608
IS - 1
ER -